|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126825 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-16 17:42:25 |
|
注册时间: Date of Registration: |
2026-06-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
髂筋膜间隙阻滞早期介入老年髋部骨折疼痛管理用于改善术后康复的临床研究 |
|
Public title: |
The early intervention of fascia iliaca compartment block (FICB) as pain management for elderly patients with hip fracture to improve postoperative rehabilitation: A prospective randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
髂筋膜间隙阻滞早期介入老年髋部骨折疼痛管理用于改善术后康复的临床研究 |
|
Scientific title: |
The early intervention of fascia iliaca compartment block (FICB) as pain management for elderly patients with hip fracture to improve postoperative rehabilitation: A prospective randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王赛洋 |
研究负责人: |
赵延华 |
|
Applicant: |
Saiyang Wang |
Study leader: |
Zhao Yanhua |
|
申请注册联系人电话: Applicant telephone: |
+86 15392583362 |
研究负责人电话:
Study leader's |
+86 21 58752345 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2574319205@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
18017464717@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦建路160号 |
研究负责人通讯地址: |
上海市浦建路160号 |
|
Applicant address: |
Renji hospital |
Study leader's address: |
No.160, Pujian Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Applicant's institution: |
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Affiliation of the Leader: |
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LY2026-057-B |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属仁济医院研究伦理分委会B组 |
||
|
Name of the ethic committee: |
Shanghai Jiaotong University School of Medicine Renji Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-05 00:00:00 | ||
|
伦理委员会联系人: |
陆麒 |
||
|
Contact Name of the ethic committee: |
Lu Qi |
||
|
伦理委员会联系地址: |
上海市浦建路160号 |
||
|
Contact Address of the ethic committee: |
No.160, Pujian Road, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 58752345 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
rjluqi@hotmail.com |
|
研究实施负责(组长)单位: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市浦建路160号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.160, Pujian Road, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self selected topic (self funded) |
||||||||||||||||||||||
|
研究疾病: |
髋部骨折 |
||||||||||||||||||||||
|
Target disease: |
hip fracture |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价髂筋膜间隙阻滞早期介入老年髋部骨折疼痛管理对术后康复质量的改善作用 |
||||||||||||||||||||||
|
Objectives of Study: |
The evaluation of the early intervention of fascia iliaca compartment block (FICB) as pain management for elderly patients with hip fracture to improve postoperative rehabilitation |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄≥65岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >=65 years old; 2. Diagnosed as hip fracture, such as a unilateral femoral neck fracture or an intertrochanteric (intro-trochanteric) fracture via imaging (X-ray, CT or MRI); 3. Planned hip surgery under general anaesthesia with endotracheal intubation due to a hip fracture (total hip replacement, partial hip replacement, intertrochanteric intramedullary nailing, closed reduction and internal fixation, etc.); 4. ASA I–III; 5. Informed consent from the patient or their legal representative; 6. Able to communicate fluently in Chinese. |
||||||||||||||||||||||
|
排除标准: |
1.罗哌卡因或布比卡因/脂质体过敏; 2.存在神经阻滞禁忌症(神经损伤、凝血功能障碍,穿刺部位严重感染、渗液等); 3.既往有精神和神经疾病如抑郁症、严重中枢神经抑制状态、帕金森症、基底神经节病变、精神分裂症、癫痫、阿兹海默症、重症肌无力; 4.既往有严重心肺肝肾功能异常如心衰史、需透析治疗等; 5.术前无法交流(昏迷或痴呆); 6.术前疼痛评分(VAS评分)<4分或陈旧性髋部骨折; 7.目前正在参加其他临床试验者; 8.研究者认为将无法评价疗效或不大可能完成预期的疗程和随访等不适宜参加本试验的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Allergy to ropivacaine or bupivacaine/liposomes; 2. Contraindications to nerve block (nerve damage, coagulation disorders, severe infection or exudate at the puncture site, etc.); 3. A history of psychiatric or neurological disorders such as depression, severe central nervous system depression, Parkinson’s disease, basal ganglia disorders, schizophrenia, epilepsy, Alzheimer’s disease or myasthenia gravis; 4. A history of severe abnormalities in cardiac, pulmonary, hepatic or renal function, such as heart failure or the need for dialysis; 5. Unable to communicate before the surgery (due to coma or dementia); 6. Preoperative pain score (VAS score) < 4 or old hip fracture; 7. Participants currently enrolled in other clinical trials; 8. Researchers consider that participants are unsuitable for this trial if they are unable to assess treatment efficacy or are unlikely to complete the intended course of treatment and follow-up. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-15 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-07-01 00:00:00 至 To 2027-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用SAS 软件中的PLAN过程产生随机号,将144名受试者按照1:1的比例随机分入早期介入组和非早期介入组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random numbers were generated using the PLAN procedure in SAS software, and the 144 participants were randomly assigned in a 1:1 ratio to the early intervention group and the non-early intervention group |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签,对评估者设盲 |
|
Blinding: |
Open-label study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
don‘t share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
临床试验相关的数据将被输入一个电子的病例报告表(eCRF)中,这些数据由研究人员从患者的病历文件、电子病历系统的源数据中获得,以及通过与患者/委托人面谈或视频电话随访获得。 所有的原始记录(包括受试者知情同意书、CRF、研究量表以及相关通信文件)将存档15年;数据将按照国家法律进行处理;数据管理将由上海交通大学附属仁济医院临床研究伦理委员会进行检查。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data relating to the clinical trial will be entered into an electronic case report form (eCRF). This data will be obtained by investigators from patients’ medical records, source data from the electronic health record system, and through follow-up interviews or video calls with patients or the sponsor.All source documents (including subject informed consent forms, CRFs, study questionnaires and relevant correspondence) will be archived for 15 years; data will be processed in accordance with national legislation; data management will be reviewed by the Clinical Research Ethics Committee of Renji Hospital, Shanghai Jiao Tong University. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |